文献速递胸部肿瘤

早期非小细胞肺癌治疗后残留ctDNA可预测早期复发

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
PubMed 文献 · Ann Oncol · 2022-03-17

该研究分析了88例早期非小细胞肺癌患者(I/II/III期分别占48.9%/28.4%/22.7%)的363份连续血浆样本,采用患者特异性RaDaR检测法追踪ctDNA。治疗后2周至4个月检出ctDNA与更短的无复发生存期(HR 14.8,P<0.00001)和总生存期(HR 5.48,P<0.0003)相关。

要点

  • 治疗后2周至4个月检出ctDNA者无复发生存期更短(HR 14.8,P<0.00001)。
  • 治疗后该窗口检出ctDNA者总生存期更短(HR 5.48,P<0.0003)。
  • 治疗前检出ctDNA与更短总生存期和无复发生存期相关(HR 2.97和3.14)。

核心结论

  • 采用敏感的患者特异性检测法在早期NSCLC初始治疗后检出ctDNA,有潜力识别可能从进一步治疗干预中获益的患者。

研究设计与样本

  • 分析88例早期NSCLC患者(I/II/III期分别占48.9%/28.4%/22.7%)的363份连续血浆样本,以治愈为目的接受手术(n=61)、手术联合辅助化疗/放疗(n=8)或放化疗(n=19)。
  • 以肿瘤外显子测序识别体细胞突变,采用患者特异性RaDaR检测法分析血浆,最多靶向48个扩增子。

主要发现

  • 治疗前ctDNA在I期、II期和III期患者中检出率分别为24%、77%和87%,在所有纵向样本中检出率为26%。
  • 检出的中位肿瘤分数为0.042%,63%的样本<0.1%,36%的样本<0.01%。
  • ctDNA检测的临床特异性>98.5%,较原发肿瘤的临床复发检测中位提前212.5天。
  • 在28例原发肿瘤临床复发患者中,18例(64.3%)治疗后检出ctDNA。
  • 治疗结束后2周至4个月的关键时间点内检出ctDNA者占17%,与更短的无复发生存期(HR 14.8,P<0.00001)和总生存期(HR 5.48,P<0.0003)相关。

关键数值与推荐

  • 治疗后2周至4个月检出ctDNA与更短无复发生存期相关(HR 14.8,P<0.00001)。
  • 治疗后2周至4个月检出ctDNA与更短总生存期相关(HR 5.48,P<0.0003)。
  • 治疗前检出ctDNA与更短总生存期(HR 2.97,P=0.01)和无复发生存期(HR 3.14,P=0.003)相关。
  • 术后1至3天检出ctDNA者占25%,但与疾病复发无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) following treatment with curative intent holds promise to identify patients at risk of relapse. New methods can detect circulating tumour DNA (ctDNA) in plasma to fractional concentrations as low as a few parts per million, and clinical evidence is required to inform their use. PATIENTS AND METHODS: We analyzed 363 serial plasma samples from 88 patients with early-stage NSCLC (48.9%/28.4%/22.7% at stage I/II/III), predominantly adenocarcinomas (62.5%), treated with curative intent by surgery (n = 61), surgery and adjuvant chemotherapy/radiotherapy (n = 8), or chemoradiotherapy (n = 19). Tumour exome sequencing identified somatic mutations and plasma was analyzed using patient-specific RaDaR™ assays with up to 48 amplicons targeting tumour-specific variants unique to each patient. RESULTS: ctDNA was detected before treatment in 24%, 77% and 87% of patients with stage I, II and III disease, respectively, and in 26% of all longitudinal samples. The median tumour fraction detected was 0.042%, with 63% of samples <0.1% and 36% of samples <0.01%. ctDNA detection had clinical specificity >98.5% and preceded clinical detection of recurrence of the primary tumour by a median of 212.5 days. ctDNA was detected after treatment in 18/28 (64.3%) of patients who had clinical recurrence of their primary tumour. Detection within the landmark timepoint 2 weeks to 4 months after treatment end occurred in 17% of patients, and was associated with shorter recurrence-free survival [hazard ratio (HR): 14.8, P <0.00001] and overall survival (HR: 5.48, P <0.0003). ctDNA was detected 1-3 days after surgery in 25% of patients yet was not associated with disease recurrence. Detection before treatment was associated with shorter overall survival and recurrence-free survival (HR: 2.97 and 3.14, P values 0.01 and 0.003, respectively). CONCLUSIONS: ctDNA detection after initial treatment of patients with early-stage NSCLC using sensitive patient-specific assays has potential to identify patients who may benefit from further therapeutic intervention.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gale D, Heider K, Ruiz-Valdepenas A, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol. 2022. PMID: 35306155. doi:10.1016/j.annonc.2022.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。